Jonathan Yingling
About Jonathan Yingling
Chief Scientific Officer at Arcus Biosciences
Jonathan Yingling has been serving as the Chief Scientific Officer at Arcus Biosciences. He joined the company in 2020 as the Senior Vice President of Research. Yingling plays a crucial role in leading the company's scientific research and development initiatives. His expertise is instrumental in driving Arcus Biosciences' mission to discover and develop innovative therapies.
Senior Leadership Roles in Pharmaceutical Companies
Jonathan Yingling has held senior leadership positions in several prominent pharmaceutical companies, including Bristol-Myers Squibb (BMS), Eli Lilly, Idera Pharmaceuticals, and Bind Therapeutics. At BMS, he was the Vice President of Oncology Discovery & Translational Research. He later joined Lilly as Vice President of Oncology Research and then became the Vice President of Translational Science & Technology. Yingling also served as the Chief Scientific Officer at both Idera Pharmaceuticals and Bind Therapeutics.
Drug Discovery and Development Contributions
Jonathan Yingling has been involved in the discovery and development of more than 15 drug candidates, including notable projects such as galunisertib and merestinib. His work has significantly contributed to advancing therapeutic options in oncology and other medical fields. Yingling's contributions demonstrate his deep commitment to improving patient outcomes through scientific innovation.
Global Research and Translational Science Partnerships
Jonathan Yingling has established and led numerous global research and translational science partnerships across the U.S., Singapore, China, and Europe. These partnerships have bolstered the collaborative efforts in scientific research, enhancing the development of new therapies. Yingling's leadership in these partnerships highlights his ability to foster global collaboration in the scientific community.
Educational Background and Research Contributions
Jonathan Yingling earned a PhD in Cell and Molecular Biology and Pharmacology from Duke University. He was also a Howard Hughes Postdoctoral Fellow at Vanderbilt University. Yingling has co-authored 65 scientific papers and is listed as an inventor in 2 issued U.S. patents. His academic and research contributions have made a significant impact on the scientific community.